Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.92 |
| ▸ | PGR | P06401 | 3/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | APEX1 | P27695 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.92 |
| ▸ | IKBKB | O14920 | 1/20 | 0.92 |
| ▸ | CHUK | O15111 | 1/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.92 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.92 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.92 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL43108 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL509818 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL515750 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7521 | 1.00 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL28843099 | 0.99 | HIF1A (0.90) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4188771 | 0.99 | HIF1A (0.90) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL8077644 | 0.98 | HIF1A (0.89) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL28161851 | 0.98 | HIF1A (0.89) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29137991 | 0.97 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL120210 | 0.96 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20250295608-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250288599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-18 | — | — | US | claimed |
| US-20250170069-A1 | NANOPREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD AND USE THEREOF | XIANGYA HOSPITAL CENTRAL SOUTH UNIV (CN) | 2025-05-29 | — | — | US | claimed |
| EP-4470532-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Xiangya Hospital, Central South University (CN) | 2024-12-04 | — | — | EP | claimed |
| CN-118662643-A | Application of hormone medicine composition in preparation of medicine for treating osteoarthritis | 中南大学湘雅医院 | 2024-09-20 | — | — | CN | claimed |
| CN-118141602-A | Lacrimal canaliculus embolism | 上海曙瑞科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2023160631-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中南大学湘雅医院 | 2023-08-31 | — | — | WO | claimed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-116098866-A | Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-12 | — | — | CN | claimed |
| US-10588913-B2 | Aqueous suspension agent containing glucocorticosteroid nanoparticles | ACTIVUS PHARMA CO., LTD. (JP) | 2020-03-17 | — | — | US | claimed |
| US-20180117064-A1 | AQUEOUS SUSPENSION AGENT CONTAINING GLUCOCORTICOSTEROID NANOPARTICLES | FORMOSA PHARMACEUTICALS, INC. (TW) | 2018-05-03 | — | — | US | claimed |
| EP-3295943-A1 | AQUEOUS SUSPENSION AGENT COMPRISING GLUCOCORTICOSTEROID NANOPARTICLES | Activus Pharma Co., Ltd. (JP) | 2018-03-21 | — | — | EP | claimed |
| CN-107613985-A | Aqueous suspensions of nanoparticles containing glucocorticoids | 株式会社活效制药 | 2018-01-19 | — | — | CN | claimed |
| EP-2050439-B1 | PROCESS FOR PRODUCTION OF SPHERICAL GRANULE CONTAINING SLIGHTLY WATER-SOLUBLE SUBSTANCE | ASAHI CHEMICAL IND (JP) | 2016-11-23 | — | — | EP | claimed |
| US-9095512-B2 | Method for producing spherical base granules comprising hardly water-soluble drug | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-08-04 | — | — | US | claimed |
| US-20090012051-A1 | EXTERNAL PREPARATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | claimed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1810692-A1 | REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-25 | — | — | EP | claimed |
| US-5236906-A | Adrenocortical hormone and hyaluronic acid; skin diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012051-A1 | EXTERNAL PREPARATION | CYP4A11, CYP46A1, CYP11B2 | NR3C1 556/4885HIF1A 1229/4885CYP3A4 91/4885 |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | PDE4A, PDE3B, PDE2A | NR3C1 62/4885HIF1A 2269/4885CYP3A4 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.